Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.25 +2.3%	$7.50	$5.90 ▼ $29.61	$532.30M	2.22	2.18 million shs	1.01 million shs
AVTX Avalo Therapeutics	$9.09 +0.7%	$6.07	$3.39 ▼ $16.00	$119.47M	0.8	113,946 shs	108,598 shs
ETON Eton Pharmaceuticals	$16.52 -3.1%	$14.83	$3.96 ▼ $21.48	$443.25M	1.13	368,973 shs	192,027 shs
SVRA Savara	$3.04 -0.2%	$2.39	$1.89 ▼ $4.70	$524.57M	0.4	1.23 million shs	770,915 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	+12.72%	-3.54%	+8.58%	-71.51%
AVTX Avalo Therapeutics	0.00%	+1.01%	+44.32%	+125.50%	-0.55%
ETON Eton Pharmaceuticals	0.00%	-0.58%	+13.45%	-12.93%	+322.83%
SVRA Savara	0.00%	+15.15%	+34.51%	-2.88%	-30.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.8688 of 5 stars	4.3	3.0	2.8	2.5	1.3
AVTX Avalo Therapeutics	3.3091 of 5 stars	3.5	5.0	2.6	1.7	0.6
ETON Eton Pharmaceuticals	2.5773 of 5 stars	3.5	1.0	3.8	1.7	0.6
SVRA Savara	3.1336 of 5 stars	4.4	0.0	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$19.76	172.48% Upside
AVTX Avalo Therapeutics	3.00	Buy	$30.00	230.21% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	79.63% Upside
SVRA Savara	2.83	Moderate Buy	$6.17	103.19% Upside

Current Analyst Ratings Breakdown

Latest AVTX, ARVN, ETON, and SVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
8/15/2025	SVRA Savara	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$5.00 ➝ $6.00
8/15/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$2.00 ➝ $5.00
8/7/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $18.00
8/7/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $16.00
8/7/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	2.02	N/A	N/A	$8.17 per share	0.89
AVTX Avalo Therapeutics	$440K	271.52	N/A	N/A	$12.80 per share	0.71
ETON Eton Pharmaceuticals	$39.01M	11.35	N/A	N/A	$0.94 per share	17.57
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$1.01	N/A	N/A	N/A	-19.47%	-12.01%	-6.97%	10/29/2025 (Estimated)
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	-48.48%	-35.94%	11/6/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	33.03	N/A	-7.10%	-0.73%	-0.22%	N/A
SVRA Savara	-$95.88M	-$0.50	N/A	N/A	N/A	N/A	-69.05%	-54.84%	N/A

Latest AVTX, ARVN, ETON, and SVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A
8/7/2025	Q2 2025	AVTX Avalo Therapeutics	-$1.43	-$1.92	-$0.49	-$1.92	N/A	N/A
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	-$0.84	+$0.03	-$0.84	$34.42 million	$22.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	5.64	5.64
AVTX Avalo Therapeutics	N/A	12.44	12.44
ETON Eton Pharmaceuticals	1.14	1.77	1.16
SVRA Savara	0.25	11.08	11.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
AVTX Avalo Therapeutics	87.06%
ETON Eton Pharmaceuticals	27.86%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
AVTX Avalo Therapeutics	0.25%
ETON Eton Pharmaceuticals	14.89%
SVRA Savara	5.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	73.42 million	69.95 million	Optionable
AVTX Avalo Therapeutics	40	13.15 million	13.12 million	Not Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.83 million	Optionable
SVRA Savara	20	172.84 million	163.97 million	Optionable

AVTX, ARVN, ETON, and SVRA Headlines

Recent News About These Companies

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

August 18 at 8:05 AM | businesswire.com

Savara (NASDAQ:SVRA) Shares Gap Up Following Analyst Upgrade

August 17 at 12:29 PM | marketbeat.com

Savara (NASDAQ:SVRA) Given New $6.00 Price Target at Oppenheimer

August 17 at 10:47 AM | marketbeat.com

Savara (NASDAQ:SVRA) Upgraded at HC Wainwright

August 17 at 9:28 AM | marketbeat.com

Oppenheimer Issues Positive Forecast for Savara (NASDAQ:SVRA) Stock Price

August 17 at 2:00 AM | americanbankingnews.com

Savara (NASDAQ:SVRA) Stock Price Up 8% - Should You Buy?

August 16 at 1:18 PM | marketbeat.com

HC Wainwright & Co. Upgrades Savara (SVRA)

August 16 at 4:13 AM | msn.com

Savara (NASDAQ:SVRA) Shares Gap Up on Analyst Upgrade

August 16 at 2:39 AM | americanbankingnews.com

Savara (NASDAQ:SVRA) Releases Earnings Results, Misses Expectations By $0.02 EPS

August 15 at 6:55 PM | marketbeat.com

Savara upgraded to Buy from Neutral at H.C. Wainwright

August 15 at 6:07 PM | msn.com

H.C. Wainwright upgrades Savara to Buy on resubmission prospects

August 15 at 6:07 PM | msn.com

Savara upgraded at H.C. Wainwright on potential refiling of marketing application

August 15 at 6:07 PM | msn.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 15 at 4:23 AM | marketbeat.com

Savara Inc. (SVRA) Stock Price Today - WSJ

August 15 at 2:01 AM | wsj.com

Savara reports Q2 EPS (14c), consensus (12c)

August 14, 2025 | msn.com

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

August 14, 2025 | theglobeandmail.com

Savara Inc. Reports Increased Loss Amid Ongoing R&D Investments

August 13, 2025 | tipranks.com

Savara (SVRA) to Release Earnings on Monday

August 9, 2025 | americanbankingnews.com

Savara (SVRA) Projected to Post Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Invests $381,000 in Savara Inc. (NASDAQ:SVRA)

August 4, 2025 | marketbeat.com

Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating

August 1, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX, ARVN, ETON, and SVRA Company Descriptions

Arvinas NASDAQ:ARVN

$7.25 +0.16 (+2.30%)

As of 02:45 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Avalo Therapeutics NASDAQ:AVTX

$9.09 +0.07 (+0.72%)

As of 02:44 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Eton Pharmaceuticals NASDAQ:ETON

$16.52 -0.53 (-3.08%)

As of 02:44 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Savara NASDAQ:SVRA

$3.04 -0.01 (-0.16%)

As of 02:45 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time